Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
LEXINGTON, Mass., April 30, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.
馬薩諸塞州列剋星敦，2024 年 4 月 30 日/PRNewswire/--專注於開發口服小分子 IRAK4 抑制劑emavusertib（CA-4948）的生物技術公司Curis, Inc.（納斯達克股票代碼：CRIS）今天宣佈，該公司將於美國東部時間2024年5月7日星期二上午8點發布其2024年第一季度財務業績。管理層將在美國東部時間當天上午 8:30 舉行電話會議。
To access the live conference call, please dial (800)-836-8184 from the United States or (646)-357-8785 from other locations, shortly before 8:30 a.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.
要觀看實時電話會議，請在美國東部時間上午8點30分前不久從美國撥打（800）-836-8184或從其他地點撥打（646）-357-8785。電話會議也可以在Curis網站上訪問，網址爲 www.curis.com 在 “投資者” 部分。電話會議結束後不久，將在Curis網站上重播電話會議。
About Curis, Inc.
關於 Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge to Genentech, a member of the Roche Group, under which they are commercializing Erivedge for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com
Curis 是一家生物技術公司，專注於開發 emavusertib，這是一種口服可口服的小分子 IRAK4 抑制劑。Emavusertib目前正在與BTK抑制劑依魯替尼聯合對復發/難治性原發性中樞神經系統淋巴瘤（PCNSL）患者進行1/2期TakeAIM淋巴瘤研究的單一療法，進行鍼對復發/難治性急性髓系白血病（AML）和復發/難治性高發性白血病（AML）患者的1/2期TakeAIM白血病研究中的單一療法風險骨髓增生異常綜合徵（HRMD），兩者均已獲得美國食品藥品監督管理局頒發的孤兒藥稱號。在急性髓細胞白血病專利中，Emavusertib還被評估爲阿扎胞苷和venetoclax的一線聯合療法。通過在2015年與Aurigene的合作，Curis獲得了emavusertib（CA-4948）的獨家許可。Curis將其對Erivedge的權利許可給了羅氏集團的成員基因泰克，根據該公司，他們正在將用於晚期基底細胞癌治療的Erivedge商業化。欲了解更多信息，請訪問 Curis 的網站 www.curis.com
SOURCE Curis, Inc.
來源 Curis, Inc.
譯文內容由第三人軟體翻譯。